2019 American Transplant Congress
Angiotensin II Type 1 Receptor Antibodies Improve Risk Stratification for Kidney Allograft Outcomes at the Time of Transplantation
*Purpose: Current state-of-the-art pre-transplant risk stratification relies on the HLA system. Non-HLA agonistic angiotensin II type 1 receptor antibodies (AT1R-Ab) have been associated with allograft…2019 American Transplant Congress
Neutralization of Interlukin-6 by ALD518-P18 (Murine Clazakizumab) Attenuates Donor Specific Antibody Responses in a Mouse Model of Allogeneic Sensitization: A Report of Dosage Finding Study
Cedars-Sinai Med Ctr, Los Angeles, CA
*Purpose: Interleukin-6 (IL-6) is a proinflammatory cytokine involved in mediating both T-cell and B-cell responses in allograft rejection. In previous studies, we demonstrated that inhibition…2019 American Transplant Congress
Dual Targeting Desensitization with Carfilzomib Plus Lulizumab Significantly Prolongs Kidney Transplant Survival in Allosensitized Nonhuman Primates
Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: Sensitized patients are difficult to transplant due to pre-formed immunity against MHC antigens; thus, new strategies for desensitization are needed to improve outcomes in…2019 American Transplant Congress
Anti-HLA Antibodies Are Associated with Deterioration in Long-Term Renal Function Independently of Donor Specificity
*Purpose: Donor-specific antibodies (DSA) negatively impact graft survival, the clinical relevance of non-donor-specific anti-HLA antibodies (NDSA) is unclear. Hence, the purpose of our study is…2019 American Transplant Congress
Success in Lung Transplantation Outcomes after Receiving a Standardized Desensitization Therapy
*Purpose: With a goal to develop a safe, effective, and consistent approach to desensitization therapy using IVIg in lung transplant (LuT), we instituted a standard…2019 American Transplant Congress
Adjunctive Therapy With Tocilizumab For Treatment Of Acute Antibody Mediated Rejection – 2 Year Experience
Washington University, St. Louis, MO
*Purpose: Reporting our center's experience in use of tocilizumab for treatment of antibody mediated rejection*Methods: We have previously reported the efficacy of Tocilizumab (TCZ), an…2019 American Transplant Congress
Unos Analysis Of Deceased Donor Renal Transplant (ddrtx) Outcomes In Sensitized Patients After Implementation Of The Kidney Allocation System (kas)
Columbia University Irving Medical Center, New York, NY
*Purpose: Introduction of KAS in 2014 prioritized access to DDRTx for highly-sensitized candidates although it was unclear whether the outcomes would be acceptable in this…2019 American Transplant Congress
Novel In Vitro Germinal Center Culture System Demonstrates More Aggressive B Cell to Plasma Blast Differentiation in Allosensitized Nonhuman Primates
Department of Surgery, Duke University Medical Center, Durham, NC
*Purpose: The allogeneic humoral immune response is largely composed of T cell dependent antibody responses produced after B and T cells interact within the germinal…2019 American Transplant Congress
Memory T Follicular Helper Cell Alloresponse is Memory B Cell Independent and Inhibited by CD28 Costimulation Blockade
Emory University School of Medicine, Atlanta, GA
*Purpose: Donor-directed HLA antibodies are an important cause of renal allograft injury, but reliable and durable therapeutic options to prevent or eliminate donor-specific antibodies (DSA)…2019 American Transplant Congress
Post-Transplant Cancer Following Living Donor HLA-Incompatible Kidney Transplantation
1Johns Hopkins University, Baltimore, MD, 2University of Alabama, Birmingham, AL
*Purpose: Incompatible living donor kidney transplantation (ILDKT) recipients require increased immunosuppression compared to their compatible living donor kidney transplant (CLDKT) counterparts. This continued exposure to…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 19
- Next Page »